CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand

Phase 3Neutral
AI Analysis

Summary

NodThera, a decade-old biotech focused on the NLRP3 anti-inflammatory pathway, announced plans to initiate a Phase 3 trial in 2027 and is rebranding to Rezera.

Clinical Trial Data

Phase

3

Outcome Details

Phase 3 trial planned for 2027

Importance:5/10
Sentiment:
0.20
NLRP3anti-inflammatoryPhase_3_planningrebrandclinical_development

Read the original article

Published by Endpoints News on September 9, 2026 11:01 AM

Read Original